At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 40 enrolled
Drug / intervention
Botulinum toxin type A +1 morebiological
Likely dose
Botulinum toxin type A 200 Unitsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Double-blind, Placebo-controlled, Randomised, Multicentre Study on the Efficacy and Safety of a Single Injection of Botulinum Toxin A (200 Units Dysport®) in the Treatment of Chronic Plantar Fasciitis
In Brief
A Phase 3 clinical trial evaluating Botulinum toxin type A and Placebo for Chronic Plantar Fasciitis. Completed, enrolled 40 participants across 6 sites.
Detailed Summary
This study will investigate the hypothesis that the analgesic effect of a single injection of Dysport (200 MU) induces a significant reduction of symptoms in chronic cases of plantar fasciitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Plantar Fasciitis
CountriesGermany
Collaborators--
Timeline
Phase 3CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2005
First PostedMar 2007
Primary CompletionJan 2009
Study CompletionApr 2009
TodayJul 2026
First PostedMar 15, 2007
Enrollment StartJul 1, 2005
Primary CompletionJan 1, 2009
Study CompletionApr 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 19.3 years ago
Interventions
Botulinum toxin type Abiological
Botulinum type A toxin (Dysport®): 200 Units injected at the root of the plantar fascia
Placebodrug
0.9% sodium chloride: 2 ml injected at the root of the plantar fascia